Alzamend Neuro, Inc.
ALZN · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $51 | $0 | $0 | $0 |
| Gross Profit | -$51 | -$51 | -$23 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,415 | $6,455 | $7,446 | $5,201 |
| G&A Expenses | $0 | $3,483 | $6,682 | $7,118 |
| SG&A Expenses | $3,031 | $3,483 | $7,425 | $7,118 |
| Sales & Mktg Exp. | $0 | $0 | $743 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,446 | $9,938 | $14,870 | $12,320 |
| Operating Income | -$4,497 | -$9,938 | -$14,870 | -$12,320 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$18 | -$10 | -$8 | -$43 |
| Pre-Tax Income | -$4,515 | -$9,948 | -$14,878 | -$12,362 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,515 | -$9,948 | -$14,878 | -$12,362 |
| % Margin | – | – | – | – |
| EPS | -11.32 | -14.72 | -2.25 | -20.92 |
| % Growth | 23.1% | -554.2% | 89.2% | – |
| EPS Diluted | -11.32 | -14.7 | -2.25 | -2.1 |
| Weighted Avg Shares Out | 451 | 3,380 | 3,250 | 2,965 |
| Weighted Avg Shares Out Dil | 451 | 3,383 | 3,251 | 2,970 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $18 | $10 | $8 | $47 |
| Depreciation & Amortization | $51 | $51 | $23 | $4 |
| EBITDA | -$4,446 | -$9,887 | -$14,847 | -$12,316 |
| % Margin | – | – | – | – |